Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Analgesics

Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib

Anne Harding  |  

NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…

Opioid Use in U.S. RA Patients

  |  

Nationally, opioid use and addiction are drawing increased scrutiny. An increase in the number of overdoses and addiction to heroin and prescription pain relievers in the past decade has been attributed in part to increased prescribing of opioids for the treatment of pain by physicians. National trends suggest the rate of opioid prescribing plateaued in…

Little Evidence Shows Cannabis Helps Chronic Pain or PTSD

Lisa Rapaport  |  

(Reuters Health)—Even though pain and posttraumatic stress disorder (PTSD) are among the most common reasons people use medical marijuana in the U.S., there isn’t much proof cannabis works for either one of these conditions, two research reviews suggest. That’s because there hasn’t been enough high-quality research to produce conclusive evidence of the benefits or harms…

New Hampshire Sues Purdue Pharma over Opioid Marketing

Nate Raymond  |  

(Reuters)—New Hampshire sued OxyContin maker Purdue Pharma LP on Tuesday, joining several state and local governments in accusing the drugmaker of engaging in deceptive marketing practices that have helped fuel a national opioid addiction epidemic. The lawsuit filed in Merrimack County Superior Court claimed that Purdue Pharma significantly downplayed the risk of addiction posed by…

DEA Proposes Cutting Production of Come Opioids

Reuters Staff  |  

(Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

More Than a Third of U.S. Adults Prescribed Opioids in 2015

Andrew M. Seaman  |  

(Reuters Health)—The U.S. needs to curb excessive opioid prescribing and improve access to pain management techniques, suggests a new government study. Researchers found that more than one third of U.S. adults were prescribed the medications in 2015 and many also misused the drugs. “A very large proportion and large number of adults use these medications…

FDA Responds to New Drug Application for Baricitinib

  |  

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

FDA Asks Endo to Withdraw Opana ER Opioid

Reuters Staff  |  

(Reuters)—The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company’s shares down as much as 13%. “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer…